"Engineering of Noninfectious HIV-1-Like Particles Containing Mutant gp41 Glycoproteins as Vaccine Candidates That Allow Vaccinees to be Distinguished from HIV-1 Infectees."

According to the authors' abstract of an article published in Virology, "Many AIDS vaccine candidates under development may elicit immune responses similar to those observed in and used to screen human immunodeficiency virus type 1 (HIV-1) infected individuals. Therefore, it is important to develop vaccine candidates that incorporate antigenic markers and allow vaccinees to be distinguished from HIV-1 infectees. To this end, we introduced a series of mutations into and in the vicinity of the major immunodominant region (MIR) of gp41 (residues 598-609), a domain recognized by almost all HIV-1 infectees, and evaluated whether HIV-1 like particles incorporating such mutant glycoproteins...

Want to see the full article?

• Purchase this article for only $3.00